T cell control in autoimmune bullous skin disorders

Journal of Clinical Investigation

Volumn 116, Issue 5, 2006, Pages 1159-1166

  Hertl, Michael ^a   Eming, Rüdiger ^a   Veldman, Christian ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN G ANTIBODY;

AUTOIMMUNE SKIN DISEASE; BULLOUS SKIN DISEASE; CELL ACTIVATION; CELL FUNCTION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PATHOGENESIS; PEMPHIGOID; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH2 CELL;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; PEMPHIGOID, BULLOUS; PEMPHIGUS; SKIN DISEASES, VESICULOBULLOUS; T-LYMPHOCYTES;

EID: 33646411527     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI28547     Document Type: Review

References (58)

1. Beutner, E.H., Jordon, R.E., and Chorzelski, T.P. 1968. The immunopathology of pemphigus and bullous pemphigoid. J. Invest. Dermatol. 51:63-80.
2. Yancey, K.B., and Egan, C.A. 2000. Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations. JAMA. 284:350-356.
3. Stanley, J.R. 1989. Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases. J. Clin. Invest. 83:1443-1448.
4. Hertl, M. 2000. Humoral and cellular autoimmunity in autoimmune bullous skin disorders. Int. Arch. Allergy Immunol. 122:91-100.
5. Borradori, L., and Sonnenberg, A. 1996. Hemidesmosomes: roles in adhesion, signaling and human diseases. Curr. Opin. Cell Biol. 8:647-656.
6. Egan, C.A., Brown, M., White, J.D., and Yancey, K.B. 2001. Treatment of epidermolysis bullosa acquisita with the humanized anti-Tac mAb daclizumab. Clin. Immunol. 101:146-151.
7. Hallel-Halevy, D., Nadelman, C., Chen, M., and Woodley, D.T. 2001. Epidermolysis bullosa acquisita: update and review. Clin. Dermatol.19:712-718.
8. Sardy, M., Karpati, S., Merkl, B., Paulsson, M., and Smyth, N. 2002. Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J. Exp. Med. 195:747-757.
9. Caproni, M., Cardinali, C., D'Agata, A., Selvaggi, W., and Fabbri, P. 2002. Serum eosinophil cationic protein, myeloperoxidase, tryptase, eotaxin and Th2-like cytokines in Dermatitis herpetiformis. Int. Arch. Allergy Immunol. 128:67-72.
10. Hertl, M., and Veldman, C. 2001. Pemphigus - paradigm of autoantibody-mediated autoimmunity. Skin Pharmacol. Appl. Skin Physiol. 14:408-418.
11. Amagai, M., Karpati, S., Prussick, R., Klaus-Kovtun, V., and Stanley, J.R. 1992. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J. Clin. Invest. 90:919-926.
12. Anhalt, G.J., Labib, R.S., Voorhees, J.J., Beals, T.F., and Diaz, L.A. 1982. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N. Engl. J. Med. 306:1189-1196.
13. Hertl, M., et al. 1998. Recognition of desmoglein 3 by autoreactive T cells in pemphigus vulgaris patients and normals. J. Invest. Dermatol. 110:62-66.
14. Wucherpfennig, K.W., et al. 1995. Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc. Natl. Acad. Sci. U. S. A. 92:11935-11939.
15. Lin, M.S., et al. 1997. Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris. J. Clin. Invest. 99:31-40.
16. Rizzo, C., et al. 2005. Direct characterization of human T cells in pemphigus vulgaris reveals elevated autoantigen-specific Th2 activity in association with active disease. Clin. Exp. Dermatol. 30:535-540.
17. Eming, R., et al. 2000. Frequency analysis of autoreactive T-helper 1 and 2 cells in bullous pemphigoid and pemphigus vulgaris by enzyme-linked immunospot assay. Br. J. Dermatol. 143:1279-1282.
18. Veldman, C., et al. 2003. Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles. J. Immunol. 170:635-642.
19. Bhol, K., et al. 1995. Correlation of peptide specificity and IgG subclass with pathogenic and non-pathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc. Natl. Acad. Sci. U. S. A. 92:5239-5243.
20. Spaeth, S., et al. 2001. IgG, IgA and IgE autoantibodies against the ectodomain of desmoglein 3 in active pemphigus vulgaris. Br. J. Dermatol. 144:1183-1188.
21. Sinha, A.A., et al. 1988. A newly characterized HLA DQ beta allele associated with pemphigus vulgaris. Science. 239:1026-1029.
22. Ahmed, A.R., et al. 1990. Major histocompatibility complex haplotype studies in Ashkenazi Jewish patients with pemphigus vulgaris. Proc. Natl. Acad. Sci. U. S. A. 87:7658-7662.
23. Ahmed, A.R., et al. 1991. Major histocompatibility complex haplotypes and class II genes in non-Jewish patients with pemphigus vulgaris. Proc. Natl. Acad. Sci. U. S. A. 88:5056-5060.
24. Riechers, R., Grötzinger, J., and Hertl, M. 1999. HLA class II restriction of autoreactive T cell responses in pemphigus vulgaris: review of the literature and potential applications for the development of a specific immunotherapy. Autoimmunity. 30:183-196.
25. Hertl, M., Karr, R.W., Amagai, M., and Katz, S.I. 1998. Heterogeneous MHC II restriction pattern of autoreactive desmoglein 3 specific T cell responses in pemphigus vulgaris patients and normals. J. Invest. Dermatol. 110:388-392.
26. Veldman, C.M., et al. 2004. T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals. J. Immunol. 172:3883-3892.
27. Hacker-Foegen, M.K., Fairley, J.A., and Lin, M.S. 2003. T cell receptor gene usage in desmoglein-3-specific T lymphocytes from patients with pemphigus vulgaris. J. Invest. Dermatol. 121:1365-1372.
28. Nishifuji, K., Amagai, M., Kuwana, M., Iwasaki, T., and Nishikawa, T. 2000. Detection of antigen-specific B cells in patients with pemphigus vulgaris by enzyme-linked immunospot assay: requirement of T cell collaboration for autoantibody production. J. Invest. Dermatol. 114:88-94.
29. Lin, M.S., et al. 2000. Desmoglein-1-specific T lymphocytes from patients with endemic pemphigus foliaceus (fogo selvagem). J. Clin. Invest. 105:207-213.
30. Gebhard, K.L., et al. 2005. Ex vivo analysis of desmoglein 1-responsive T-helper (Th) 1 and Th2 cells in patients with pemphigus foliaceus and healthy individuals. Exp. Dermatol. 14:586-592.
31. Hoffman, M.A., Qiao, X., and Anhalt, G.J. 2003. CD8+ T lymphocytes in bronchiolitis obliterans, paraneoplastic pemphigus, and solitary Castleman's disease. N. Engl. J. Med. 349:407-408.
32. Liu, Z., et al. 1993. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J. Clin. Invest. 92:2480-2488.
33. Sitaru, C., et al. 2002. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J. Invest. Dermatol. 118:664-671.
34. Büdinger, L., et al. 1998. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J. Clin. Invest. 102:2082-2089.
35. Lin, M.S., et al. 2000. Epitopes targeted by bullous pemphigoid T lymphocytes and autoantibodies map to the same sites on the bullous pemphigoid 180 ectodomain. J. Invest. Dermatol. 115:955-961.
36. Hofmann, S., et al. 2002. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain. J. Invest. Dermatol. 119:1065-1073.
37. Thoma-Uszynski, S., et al. 2004. BP230- and BP180-specific auto-antibodies in bullous pemphigoid. J. Invest. Dermatol. 122:1413-1422.
38. Thoma-Uszynski, S., et al. 2006. Autoreactive T and B cells from bullous pemphigoid (BP) patients recognized epitopes clustered in distinct regions of BP180 and BP230. J. Immunol. 176:2015-2023.
39. Lin, M.S., Gharia, M.A., Swartz, S.J., Diaz, L.A., and Giudice, G.J. 1999. Identification and characterization of epitopes recognized by T lymphocytes and autoantibodies from patients with herpes gestationis. J. Immunol. 162:4991-4997.
40. Hacker-Foegen, M.K., Zillikens, D., Giudice, G.J., and Lin, M.S. 2004. T cell receptor gene usage of BP180-specific T lymphocytes from patients with bullous pemphigoid and pemphigoid gestationis. Clin. Immunol. 113:179-186.
41. Black, A.P., et al. 2004. Rapid effector function of circulating NC16A-specific T cells in individuals with mucous membrane pemphigoid. Br. J. Dermatol. 151:1160-1164.
42. Lin, M.S., et al. 2002. Autoimmune responses in patients with linear IgA bullous dermatosis: both autoantibodies and T lymphocytes recognize the NC16A domain of the BP180 molecule. Clin. Immunol. 102:310-319.
43. Delgado, J.C., et al. 1996. A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid. Proc. Natl. Acad. Sci. U. S. A. 93:8569-8571.
44. Banfield, C.C., et al. 1998. The association of HLA-DQ7 with bullous pemphigoid is restricted to men. Br. J. Dermatol. 138:1085-1090.
45. Haase, C., et al. 1998. Detection of IgG autoantibodies in the sera of patients with bullous and gestational pemphigoid: ELISA studies utilizing a baculovirus-encoded form of bullous pemphigoid antigen 2. J. Invest. Dermatol. 110:282-286.
46. Setterfield, J., et al. 2001. Mucous membrane pemphigoid: HLA-DQB1*0301 is associated with all clinical sites of involvement and may be linked to anti-basement membrane IgG production. Br. J. Dermatol. 145:406-414.
47. Koch, P.J., et al. 1997. Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris. J. Cell Biol. 137:1091-1102.
48. Amagai, M., et al. 2000. Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus. J. Clin. Invest. 105:625-631.
49. Tsunoda, K., et al. 2002. Pathogenic autoantibody production requires loss of tolerance against desmoglein 3 in both T and B cells in experimental pemphigus vulgaris. Eur. J. Immunol. 32:627-633.
50. Aoki-Ota, M., et al. 2004. A mouse model of pemphigus vulgaris by adoptive transfer of naive splenocytes from desmoglein 3 knockout mice. Br. J. Dermatol. 151:346-354.
51. Eming, R., et al. 2005. Ex vivo analysis of T cell epitopes of desmoglein 3 in a HLA class II-transgenic mouse model of pemphigus vulgaris. J. Invest. Dermatol. 125:A12.
52. Sonderstrup, G., et al. 1999. HLA class II transgenic mice: models of the human CD4+ T-cell immune response. Immunol. Rev. 172:335-343.
53. Sakaguchi, S. 2005. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6:345-352.
54. Veldman, C., Hohne, A., Dieckmann, D., Schuler, G., and Hertl, M. 2004. Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris. J. Immunol. 172:6468-6475.
55. Sinha, E., et al. 2005. Elevation of antigen specific CD8+ CD28- cells in newly remittent patients with pemphigus vulgaris. J. Invest. Dermatol. 125:1084A.
56. Veldman, C., et al. 2006. Inhibition of the transcription factor Foxp3 converts desmoglein 3-specific type 1 regulatory T cells into autoreactive T helper 2-like cells. J. Immunol. 176:3215-3222.
57. Veldman, C., Nagel, A., and Hertl, M. 2006. Type 1 regulatory T cells in autoimmunity and inflammatory diseases. Int. Arch. Allergy Immunol. In press.
58. Yancey, K.B. 2005. The pathophysiology of autoimmune blistering diseases. J. Clin. Invest. 115:825-828. doi:10.1172/JCI200524855.